Longer Treatment Durations and the Launch of Novel Treatments Will Grow the Drug Market for Chronic Myelogenous Leukemia
Posted by rob on May 27, 2005 under Uncategorized | 
Be the First to Comment
Decision Resources, Inc., one of the world’s leading research and advisory firms focusing on pharmaceutical and health care issues, finds that longer treatment durations and the launch of novel treatments will grow the drug market for chronic myelogenous leukemia almost 12% annually between 2004 and 2009. Novel agents such as those from Bristol-Myers Squibb and Novartis will increase patient drug consumption by offering a viable, and likely durable, second-line pharmacological approach to the treatment of chronic myelogenous leukemia.
Add A Comment
You must be logged in to post a comment.